NASDAQ
7.98USD
+0.90 (+12.71%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
407.2M
P/E
—
EPS
—
Beta
0.53
52W range
2.96-40.37
Day range
7.15–7.99
Open
7.17
Prev close
7.08
Volume
8.3M
Avg volume
3.4M
Dividend
0.00
IPO
2007-02-13
https://www.globenewswire.com/news-release/2026/08/17/3346453/34548/en/deadline-alert-capricor-therapeutics-inc-capr-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html · 8/17/2026-1.00
https://www.globenewswire.com/news-release/2026/08/17/3345935/0/en/capr-court-news-capricor-therapeutics-securities-fraud-class-action-filed-after-clinical-data-issues-and-64-stock-drop-contact-bfa-law-before-september-28.html · 8/17/2026-1.00
https://www.newsfilecorp.com/release/309360/CAPR-INVESTOR-ALERT-Capricor-Therapeutics-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit-before-September-28-2026-Deadline · 8/16/2026-1.00
https://www.globenewswire.com/news-release/2026/08/15/3345759/0/en/nasdaq-capr-kessler-topaz-meltzer-check-llp-announces-the-filing-of-a-securities-fraud-class-action-lawsuit-against-capricor-therapeutics-inc.html · 8/15/2026-1.00
https://www.newsfilecorp.com/release/308701/Capricor-Therapeutics-Inc.-Notice-of-September-28-2026-Application-Deadline-for-Class-Action-Lawsuit-Contact-Lewis-Kahn-Esq.-at-Kahn-Swick-Foti-LLC-Before-Application-Deadline · 8/7/2026-1.00
https://www.prnewswire.com/news-releases/pnr-investor-deadline-pentair-plc-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-302845245.html · 8/6/2026-1.00
https://www.newsfilecorp.com/release/307599/ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-PROCEPT-BioRobotics-Corporation-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-PRCT · 8/1/2026-0.80
https://www.globenewswire.com/news-release/2026/07/30/3335720/32716/en/CAPR-Alert-Capricor-Therapeutics-Inc-NASDAQ-CAPR-Investors-Urged-to-Contact-Hagens-Berman-Investigation-Opened-Following-Massive-Stock-Crash.html · 7/30/2026-1.00
https://www.defenseworld.net/2026/07/26/capricor-therapeutics-sees-unusually-high-options-volume-nasdaqcapr.html · 7/26/2026+0.30
https://www.fool.com/coverage/filings/2026/07/25/this-capricor-insider-sold-24-000-shares-before-the-drop-with-a-new-catalyst-on-the-way-is-it-time-to-buy-again/ · 7/25/2026+0.00
https://www.newsfilecorp.com/release/304496/ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-Black-Rock-Coffee-Bar-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-BRCB · 7/8/2026-0.80
https://www.globenewswire.com/news-release/2026/07/05/3322099/9788/en/Bronstein-Gewirtz-Grossman-LLC-Urges-CommVault-Systems-Inc-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm.html · 7/5/2026-1.00
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
